NOV 09, 2017 10:30 AM PST

Fast Phenotypic Antibiotic Susceptibility Testing of Positive Blood Cultures

SPONSORED BY: Accelerate Diagnostics
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Professor of Pathology and Laboratory Medicine, Scientific Director and Microbiology, Cedars-Sinai Medical Center
    Biography
      I am a clinical microbiologist and currently the scientific director of microbiology at Cedars- Sinai Medical Center in Los Angeles, CA. I love to teach, and during my thirty years in microbiology I have taught enumerable pathology residents, infectious disease fellows, pharmacists, infection control nurses, and clinical laboratory scientists. I have reviewed hundreds of pathology residents for their board examination at the Osler Institute Pathology Review Course. It has been my goal to spread the science and art of microbiology to whoever would look and listen. I love to teach microbiology!

    Abstract:

    The role of the microbiology laboratory in the processing of positive patient blood cultures has become more complicated with the increasing demand for rapid information to assist in the management of sepsis.  Many laboratories have turned to using molecular systems that report identification and resistant marker results that supply actionable information but no susceptibility data.  These systems have proven over time to be useful with the management of Gram positive bloodstream infections but vary in the ability to properly guide therapy choices for Gram negative bacteremia.   In our institution, phenotypic antimicrobial susceptibility results are often necessary for optimization of therapy. This is particularly true due to emerging resistance mechanisms in Gram negative bacilli, such as AmpC and porin alterations.  The Accelerate Pheno™ system is a truly unique and divergent technology that has the potential to produce final susceptibility results directly from a positive blood culture within 7 hours.  This is a reduction in time to results from conventional susceptibility methods of 2-3 days.   The Accelerate Diagnostics system was FDA cleared in February of 2017.  Clinical trial and scientific presentations have shown the identification and MIC susceptibility results to be reliable and can be used to improve patient care.  Rapid final MIC results provide invaluable information to a stewardship program to rapidly optimize the therapy of sepsis.


    Show Resources
    You May Also Like
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    APR 25, 2018 07:00 AM PDT
    C.E. CREDITS
    APR 25, 2018 07:00 AM PDT
    DATE: April 25, 2018TIME: 1500 CET, 10:00 a.m. EST, 7:00 a.m. PST Hematology and coagulation laboratories perform a wide range of routine and specialized tests, allowing clinicians to...
    Loading Comments...